Field of Speciality: Urology
Date of Birth: 1980
School of Medicine: Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English
Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.
Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot
After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments
His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement Penile Implants , Penile Enhancement , SafeFill and MaleShot into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.
(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)
Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.
OTHER AREAS OF FOCUS
Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias
Membership of Scientific Organizations
Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications
• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en
Read moreField of Speciality: Urology
Date of Birth: 1980
School of Medicine: Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English
Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.
Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot
After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments
His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement Penile Implants , Penile Enhancement , SafeFill and MaleShot into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.
(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)
Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.
OTHER AREAS OF FOCUS
Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias
Membership of Scientific Organizations
Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications
• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en
Dr. Huseyin Bektas is a Professor of Medical Sciences, Oncosurgeon and published author. He is a Member of the Association of Hepatobiliary and Pancreatic Surgery and a Teacher at the Hanover School of Medicine. He is also the Chief Physician at the Bremen-Mitte Hospital Department of General, Visceral and Oncological Surgery.
Read moreDr. Huseyin Bektas is a Professor of Medical Sciences, Oncosurgeon and published author. He is a Member of the Association of Hepatobiliary and Pancreatic Surgery and a Teacher at the Hanover School of Medicine. He is also the Chief Physician at the Bremen-Mitte Hospital Department of General, Visceral and Oncological Surgery.
Doctor's visit | price on request |
Lung segmentectomy | $19300.8 - $26806.66 |
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | $45035.19 - $50396.52 |
Liver resection | $16084 |
Doctor's visit | price on request |
Lung segmentectomy | $19300.8 - $26806.66 |
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | $45035.19 - $50396.52 |
Liver resection | $16084 |
Dr. Markus Zutt is an experienced Dermatologist/Dermatovenereologist/Dermatologic surgeon with 18 years of experience in areas such as dermatosurgery, treating chronic wounds, laser medicine, sonography of lymph nodes and skin and vascular diagnostics. He is a Professor at University Medicine, Göttingen and a published author on various topics with expertise in allergology, drug tumour therapy, phlebology, skin and lymph node sonography and colour-coded duplex sonography.
Read moreDr. Markus Zutt is an experienced Dermatologist/Dermatovenereologist/Dermatologic surgeon with 18 years of experience in areas such as dermatosurgery, treating chronic wounds, laser medicine, sonography of lymph nodes and skin and vascular diagnostics. He is a Professor at University Medicine, Göttingen and a published author on various topics with expertise in allergology, drug tumour therapy, phlebology, skin and lymph node sonography and colour-coded duplex sonography.
Doctor's visit | price on request |
Lung segmentectomy | $19300.8 - $26806.66 |
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | $45035.19 - $50396.52 |
Liver resection | $16084 |
Head of the Bone Marrow Transplantation Department, Hematologist
Read moreHead of the Bone Marrow Transplantation Department, Hematologist
Doctor's visit | price on request |
Hysterectomy (uterus removal) | $5000 - $7000 |
Pancreatic cancer surgery | $12500 - $14450 |
Autologous bone marrow transplantation | $25000 |
Doctor's visit | price on request |
Lung segmentectomy | $19300.8 - $26806.66 |
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | $45035.19 - $50396.52 |
Liver resection | $16084 |
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Stomach Cancer
Ovarian Cancer
Read moreAssociate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Stomach Cancer
Ovarian Cancer
Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Read moreProf. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Read moreProfessor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)